2019 Industry Education
- 2019 | SGLT-2 INHIBITOR USE IN T1D
- 2019 | SANOFI SYMPOSIA
This information has been
developed for HCPs regarding the use of Dapagliflozin as adjunct therapy
in Adults with Type 1 Diabetes.
This online education was developed with an unrestricted medical education grant from AstraZeneca and is a medical information resource intended for healthcare professionals, outside of the USA and specifically in Europe, who are interested in medical information related to the use of Dapagliflozin as adjunct therapy in Adults with Type 1 Diabetes. The following resources are shared as medical information only and are not issued as medical advice from ATTD or Astra Zeneca.
At the 12th International Conference on Advanced Treatments for Diabetes (ATTD) in Berlin, Germany, Sanofi offered timely insights into the latest advances in clinical care. Our key symposia at the congress offered delegates an opportunity to see the latest data and hear expert opinion on a range of topics from continuous glucose monitoring to integrated care solutions.
Please click Enter Course to access the video content and the relevant ePosters from this event.